Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Autologous Killer Cell Injection Induced by Dendritic Dells Loaded With 6B11 Anti-idiotype Minibody (6b11 - OCIK Injection) Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer

NCT03542669 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT03542669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03542669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Autologous Killer Cell Injection Induced by Dendritic Dells Loaded With 6B11 Anti-idiotype Minibody (6b11 - OCIK Injection) Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer
Lead sponsor
Peking University People's Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
August 3, 2018
Completion date
December 30, 2023
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant ovarian cancer, recurrent ovarian carcinoma